We are updating our Privacy Policy and Terms and Conditions to help you clearly understand how your personal information is collected, stored and managed. Learn More
Menu Back toEmerging-Best-Practices-and-Challenges-in-Strategic-Drug-Development-and-Design-Decision-Making

DIA 2018 Global Annual Meeting

The DIA 2018 Global Annual Meeting brings together thousands of innovators from around the globe.


Emerging Best Practices and Challenges in Strategic Drug Development and Design Decision Making

    Session Chair(s)
      Cara  Willoughby, MS

      Cara Willoughby, MS

      • Principal Scientific Advisor
      • IQVIA, United States
    This session will present lessons learned and case examples from three different companies who have introduced change initiatives aimed at disrupting and improving strategy and design decision-making. Presentations will share common obstacles, change management pitfalls, critical success factors, and actions you can take now to improve design decision making in your company.
    Learning Objective : Compare and contrast traditional versus emerging strategic drug development and design decision-making practices; Recognize challenges often encountered when implementing new tools, data, processes, and approaches to strategic drug development and design decision-making and describe their impact; Define critical success factors for improving strategic drug development and design decision-making
    Speaker(s)
      Cara  Willoughby, MS

      Lessons Learned Translating Data to Meaningful Design Insights

      Cara Willoughby, MS

      • Principal Scientific Advisor
      • IQVIA, United States
      Kyle  Holen, MD

      Leveraging Big Data to Help Design Clinical Program Strategies

      Kyle Holen, MD

      • Head, Development Design Center
      • AbbVie, Inc., United States
      Florian  Bieber, MD

      Patient Engagement Strategies in Design

      Florian Bieber, MD

      • Global Head, Clinical Development and Analytics
      • Novartis Pharma AG, Switzerland